Aptevo Therapeutics (APVO) Liabilities and Shareholders Equity (2015 - 2026)

Aptevo Therapeutics has reported Liabilities and Shareholders Equity for 12 years, with the latest figure at $19.9 million in Q1 2026.

• Quarterly Liabilities and Shareholders Equity rose 138.58% year-over-year to $19.9 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $89.7 million (up 66.14% YoY) and the FY2025 annual result came in at $27.2 million, up 74.42% from the prior year.
• Liabilities and Shareholders Equity declined to $19.9 million in Q1 2026 per APVO's latest filing, from $27.2 million in the prior quarter.
• Over five years, Liabilities and Shareholders Equity peaked at $45.2 million in Q1 2022 and troughed at $8.3 million in Q1 2025.
• A 5-year average of $25.1 million and a median of $27.0 million in 2025 frame the typical range for Liabilities and Shareholders Equity.
• The sharpest annual moves came in 2025 and 2026: Liabilities and Shareholders Equity sank 52.68% in 2025, then jumped 138.58% in 2026.
• Over 5 years, Liabilities and Shareholders Equity stood at $34.2 million in 2022, then declined by 27.39% to $24.8 million in 2023, then plunged by 37.24% to $15.6 million in 2024, then surged by 74.42% to $27.2 million in 2025, then slipped by 26.81% to $19.9 million in 2026.
• According to Business Quant data, Liabilities and Shareholders Equity over the past three periods registered $19.9 million, $27.2 million, and $27.0 million for Q1 2026, Q4 2025, and Q3 2025 respectively.